{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:06:00Z","timestamp":1791576360973,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.clinthera.2018.09.006","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T22:59:34Z","timestamp":1540594774000},"page":"1855-1867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110\u03b4, Following Single Ascending Dose Administration to Healthy Volunteers"],"prefix":"10.1016","volume":"40","author":[{"given":"Ofir","family":"Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Zann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Willson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.09.006_bib1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamaoncol.2016.0891","article-title":"Landscape of phosphatidylinositol-3-kinase pathway alterations across 19784 diverse solid tumors","volume":"2","author":"Millis","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinthera.2018.09.006_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coph.2015.05.017","article-title":"PI3K inhibitors in inflammation, autoimmunity and cancer","volume":"23","author":"Stark","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.09.006_bib3","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood-2009-07-232330","article-title":"PI3K p110\u03b4 regulates T-cell cytokine production during primary and secondary immune responses in mice and humans","volume":"115","author":"Soond","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.09.006_bib4","doi-asserted-by":"crossref","first-page":"ra60","DOI":"10.1126\/scisignal.2001104","article-title":"The PI3K isoforms p110\u03b1 and p110\u03b4 are essential for Pre-B cell receptor signaling and B cell development","volume":"3","author":"Ramadani","year":"2010","journal-title":"Sci Signal"},{"key":"10.1016\/j.clinthera.2018.09.006_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017359","article-title":"The PI3K p110\u03b4 regulates expression of CD38 on regulatory T cells","volume":"6","author":"Patton","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2018.09.006_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clim.2017.01.004","article-title":"Genetic defects in PI3K\u03b4 affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections","volume":"176","author":"Wentink","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clinthera.2018.09.006_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cellsig.2010.10.002","article-title":"Phosphoinositide 3-kinase delta (PI3K\u03b4) in leukocyte signaling and function","volume":"23","author":"Fung-Leung","year":"2011","journal-title":"Cell Signal"},{"key":"10.1016\/j.clinthera.2018.09.006_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pharmthera.2016.12.001","article-title":"Maximising the potential of AKT inhibitors as anti-cancer treatments","volume":"172","author":"Brown","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2018.09.006_bib9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2018.09.006_bib10","series-title":"NCCN Clinical Practice Guidelines in Oncology: B-cell Lymphomas, Version 1.2017","year":"2016"},{"key":"10.1016\/j.clinthera.2018.09.006_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.09.006_bib12","series-title":"EMEA\/CHMP\/324336\/2014\u2014CHMP assessment report Zydelig","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.clinthera.2018.09.006_bib13","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bbalip.2014.12.006","article-title":"PI3K signalling in inflammation","volume":"1851","author":"Hawkins","year":"2015","journal-title":"Biochim Biophys Acta\u2014Mol Cell Biol Lipids; Phosphoinositides"},{"key":"10.1016\/j.clinthera.2018.09.006_bib14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.it.2008.07.004","article-title":"The multiple roles of phosphoinositide 3-kinase in mast cell biology","volume":"29","author":"Kim","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1016\/j.clinthera.2018.09.006_bib15","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1182\/blood.V120.21.2907.2907","article-title":"Preclinical characterization of PWT143, a novel selective and potent phosphatidylinositol 3 kinase delta (PI3K delta) inhibitor with ex-vivo activity in hematologic malignancies","volume":"120","author":"O\u2019Farrell","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.09.006_bib16","series-title":"Tripartite Guideline, Nonclinical Evaluation for Anticancer Pharmaceuticals (S9)","author":"International Conference on Harmonisation","year":"2009"},{"key":"10.1016\/j.clinthera.2018.09.006_bib17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110\u03b4 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.09.006_bib18","series-title":"Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers","author":"Food and Drug Administration (FDA)","year":"2005"},{"key":"10.1016\/j.clinthera.2018.09.006_bib19","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.clinthera.2018.09.006_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.clinthera.2018.09.006_bib21","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2018.36.15_suppl.7519","article-title":"Initial results of a dose escalation study of a selective and structurally differentiated PI3K\u03b4 inhibitor, ME-401, in relapsed\/refractory (R\/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL)","volume":"36","author":"Soumerai","year":"2018","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818304272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818304272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T21:47:38Z","timestamp":1572299258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818304272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0149291818304272"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.09.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110\u03b4, Following Single Ascending Dose Administration to Healthy Volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 MEI Pharma, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}